세계의 급성 세균성 피부 및 피부 구조 감염증 시장 : 감염 유형, 질환 카테고리, 투여 경로, 유통 채널별 예측(2025-2030년)

The Acute Bacterial Skin & Skin Structure Infection Market was valued at USD 10.52 billion in 2023, expected to reach USD 11.35 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 18.79 billion by 2030.

Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involve serious bacterial invasion of skin and its underlying tissues, encompassing conditions like cellulitis, wound infections, and abscesses. These infections are critical due to their rapid progression and potential complications, demanding prompt and effective medical intervention. ABSSSIs hold crucial application in healthcare, driving the need for advanced antibiotics and therapies. Rising incidences of such infections fuel the necessity for innovative solutions, while their treatment primarily resides within hospitals, clinics, and ambulatory surgical centers. Market dynamics are propelled by factors like increasing incidence of drug-resistant bacteria, healthcare advancements, and heightened awareness around new treatment modalities. Opportunities arise from the growing demand for new antibiotics and the need for better diagnostic tools, with significant potential in developing faster and more accurate diagnostic technologies and next-generation antimicrobials. Recommendations for capturing these opportunities include investing in R&D for novel antimicrobial drugs, forming strategic partnerships with biotech firms, and leveraging cutting-edge technology for rapid diagnostics. However, the market faces limitations such as stringent regulatory pathways, high costs of drug development, and potential side effects associated with antibiotic treatments, which could dampen growth. Strict antibiotic stewardship programs to combat resistance further complicate market penetration. The best innovation areas lie in developing combination therapies and exploring natural or synthetic alternatives with fewer resistance issues. Insights suggest that collaborations between pharmaceutical companies and research institutions are essential to drive groundbreaking solutions. The market is competitive, characterized by ongoing research efforts, revolving regulatory landscape, and demand for cost-effective solutions. Overall, innovation will be crucial in addressing unmet needs in ABSSSIs, as companies need to balance between regulatory compliance, economic feasibility, and effective therapeutic outcomes to succeed in this evolving market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Bacterial Skin & Skin Structure Infection Market

The Acute Bacterial Skin & Skin Structure Infection Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence and cases of bacterial skin infections
  • Increasing people awareness about skin problems
  • Growth in number of dermatology centers and clinics
• Market Restraints
  • Associated adverse health impacts of ABSSSI drugs
• Market Opportunities
  • Ongoing R&D activities for development of novel drugs
  • Surge in regulatory approvals from clinical authorities
• Market Challenges
  • Lack of standard protocols and mismanaged treatments

Porter's Five Forces: A Strategic Tool for Navigating the Acute Bacterial Skin & Skin Structure Infection Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Bacterial Skin & Skin Structure Infection Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Bacterial Skin & Skin Structure Infection Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Bacterial Skin & Skin Structure Infection Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Bacterial Skin & Skin Structure Infection Market

A detailed market share analysis in the Acute Bacterial Skin & Skin Structure Infection Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Bacterial Skin & Skin Structure Infection Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Bacterial Skin & Skin Structure Infection Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Bacterial Skin & Skin Structure Infection Market

A strategic analysis of the Acute Bacterial Skin & Skin Structure Infection Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Bacterial Skin & Skin Structure Infection Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Accord Healthcare Limited, Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Basilea Pharmaceutica Ltd, BiVictriX Therapeutics PLC, Cadila Pharmaceuticals Limited, Cumberland Pharmaceuticals Inc., Debiopharm SA, Destiny Pharma PLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Innovation Pharmaceuticals Inc., Intas Pharmaceuticals Ltd., KBP Biosciences Co., Ltd., Melinta Therapeutics, LLC, Merck & Co, Inc, MicuRx Pharmaceuticals, Inc., Novartis International AG, Paratek Pharmaceuticals, Inc., Pfizer Inc., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Acute Bacterial Skin & Skin Structure Infection Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Infection Type, market is studied across Community-Acquired ABSSI and Hospital Acquired ABSSI.
• Based on Disease Category, market is studied across Nonpurulent and Purulent.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence and cases of bacterial skin infections
    • 5.1.1.2. Increasing people awareness about skin problems
    • 5.1.1.3. Growth in number of dermatology centers and clinics
  • 5.1.2. Restraints
    • 5.1.2.1. Associated adverse health impacts of ABSSSI drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D activities for development of novel drugs
    • 5.1.3.2. Surge in regulatory approvals from clinical authorities
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of standard protocols and mismanaged treatments
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acute Bacterial Skin & Skin Structure Infection Market, by Infection Type

• 6.1. Introduction
• 6.2. Community-Acquired ABSSI
• 6.3. Hospital Acquired ABSSI

7. Acute Bacterial Skin & Skin Structure Infection Market, by Disease Category

• 7.1. Introduction
• 7.2. Nonpurulent
• 7.3. Purulent

8. Acute Bacterial Skin & Skin Structure Infection Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral
• 8.4. Topical

9. Acute Bacterial Skin & Skin Structure Infection Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. Americas Acute Bacterial Skin & Skin Structure Infection Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Acute Bacterial Skin & Skin Structure Infection Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Acute Bacterial Skin & Skin Structure Infection Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie, Inc.
• 2. Accord Healthcare Limited
• 3. Amneal Pharmaceuticals, Inc.
• 4. Aurobindo Pharma Limited
• 5. Basilea Pharmaceutica Ltd
• 6. BiVictriX Therapeutics PLC
• 7. Cadila Pharmaceuticals Limited
• 8. Cumberland Pharmaceuticals Inc.
• 9. Debiopharm SA
• 10. Destiny Pharma PLC
• 11. Fresenius SE & Co. KGaA
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Limited
• 14. Innovation Pharmaceuticals Inc.
• 15. Intas Pharmaceuticals Ltd.
• 16. KBP Biosciences Co., Ltd.
• 17. Melinta Therapeutics, LLC
• 18. Merck & Co, Inc
• 19. MicuRx Pharmaceuticals, Inc.
• 20. Novartis International AG
• 21. Paratek Pharmaceuticals, Inc.
• 22. Pfizer Inc.
• 23. Sun Pharmaceutical Industries Limited
• 24. Teva Pharmaceutical Industries Ltd.